Clinical Nutrition 2012-08-01

Taurolidine lock solution in the secondary prevention of central venous catheter-associated bloodstream infection in home parenteral nutrition patients.

Abdoulaye Touré, Madeleine Lauverjat, Catherine Peraldi, Michèle Boncompain-Gerard, Patrick Gelas, Didier Barnoud, Cécile Chambrier

Index: Clin. Nutr. 31(4) , 567-70, (2012)

Full Text: HTML

Abstract

Central venous catheter-associated bloodstream infection (CBSI) is a serious complication in patients on home parenteral nutrition (HPN). The aim was to analyze the impact of taurolidine-citrate lock solution (TLS) on CBSI rate in HPN patients with a high risk of catheter infection.This retrospective study compared CBSI rates 12 months before and 12 months after implementation of TLS. In the first period, only standardized strategies were used to reduce the CBSI rate. In the second period, TLS was injected into the catheter at the end of parenteral nutrition. The CBSI rate with a confident interval was calculated as Poisson event rates, and compared by testing for homogeneity of rates.15 patients were included. During the 24 months, the CBSI rate was 6.58/1000 catheter-days in the first period and 1.09/1000 catheter-days in the second period (p < 0.001). In patients with TLS once a week (n = 8), the CBSI rate decreased from 4.8/1000 catheter-days to 1.37/1000 catheter-days (p = 0.02) and in patients with TLS after each TPN (n = 7), the CBSI rate decreased from 8.61/1000 catheter-days to 0.78/1000 catheter-days (p = 0.001).In HPN patients, TLS associated with standardized precautions significantly reduced the CBSI rate.Copyright © 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.


Related Compounds

Related Articles:

Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.

2014-11-01

[Int. J. Colorectal Dis. 29(11) , 1339-48, (2014)]

Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.

2013-08-01

[Pediatr. Blood Cancer 60(8) , 1292-8, (2013)]

Taurolidine specifically inhibits growth of neuroblastoma cell lines in vitro.

2014-05-01

[J. Pediatr. Hematol. Oncol. 36(4) , e219-23, (2014)]

Efficacy of taurolidine against periodontopathic species--an in vitro study.

2012-06-01

[Clin. Oral Investig. 16(3) , 735-44, (2012)]

Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.

2012-04-01

[J. Hosp. Infect. 80(4) , 304-9, (2012)]

More Articles...